Efficacy and Safety of MEDI7352 in Participants With Painful Diabetic Neuropathy

PHASE2TerminatedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

November 19, 2018

Primary Completion Date

June 29, 2023

Study Completion Date

June 29, 2023

Conditions
Painful Diabetic Neuropathy
Interventions
DRUG

MEDI7352

Participants will receive IV infusion of MEDI7352 as stated in arm description.

OTHER

Placebo

Participants will receive IV infusion of placebo as stated in arm description.

Trial Locations (31)

1036

Research Site, Budapest

2820

Research Site, Gentofte Municipality

8230

Research Site, Balatonfüred

10117

Research Site, Olsztyn

20064

Research Site, Lublin

87100

Research Site, Torun

200505

Research Site, Craiova

540142

Research Site, Târgu Mureş

800291

Research Site, Galati

917080

Research Site, Călăraşi

85-065

Research Site, Bydgoszcz

80-382

Research Site, Gdansk

40-040

Research Site, Katowice

40-282

Research Site, Katowice

30-534

Research Site, Krakow

20-093

Research Site, Lublin

60-702

Research Site, Poznan

96-500

Research Site, Sochaczew

01-192

Research Site, Warsaw

01144

Research Site, Warsaw

53-413

Research Site, Wroclaw

011025

Research Site, Bucharest

S75 3DL

Research Site, Barnsley

FY2 0JH

Research Site, Blackpool

WS11 0BN

Research Site, Cannock

CF14 4XW

Research Site, Cardiff

LS10 1DU

Research Site, Leeds

NW10 7EW

Research Site, London

M13 9NQ

Research Site, Manchester

L34 1BH

Research Site, Prescot

TS17 6EW

Research Site, Stockton-on-Tees

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY